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Abstract: We investigated the association between the Val158Met polymorphism of the 
catechol-O-methyltransferase (COMT) gene, the Val66Met polymorphism of the brain-derived 
neurotrophic factor (BDNF) gene, and white matter changes in patients with major depres-
sive disorder (MDD) and healthy subjects using diffusion   tensor imaging (DTI). We studied 
30 patients with MDD (17 males and 13 females, with mean age ± standard deviation [SD] 
=44±12 years) and 30 sex- and age-matched healthy   controls (17 males and 13 females, aged 
44±13 years). Using DTI analysis with a tract-based spatial statistics (TBSS) approach, we 
investigated the differences in fractional anisotropy, radial diffusivity, and axial diffusivity 
distribution among the three groups (patients with the COMT gene Val158Met, those with the 
BDNF gene Val66Met, and the healthy subjects). In a voxel-wise-based group comparison, we 
found significant decreases in fractional anisotropy and axial diffusivity within the temporal 
lobe white matter in the Met-carriers with MDD compared with the controls (P,0.05). No 
correlations in fractional anisotropy, axial diffusivity, or radial diffusivity were observed 
between the MDD patients and the controls, either among those with the BDNF Val/Val 
genotype or among the BDNF Met-carriers. These results suggest an association between 
the COMT gene Val158Met and the white matter abnormalities found in the temporal lobe 
of patients with MDD.
Keywords: catechol-O-methyltransferase, brain-derived neurotrophic factor, 3-methoxy-4-
hydroxyphenylglycol, homovanillic acid
Introduction
Catecholamines play an important role in the pathogenesis of major depressive disorder 
(MDD).1 Catechol-O-methyltransferase (COMT) is a methylation enzyme that plays 
a role in the degradation of noradrenaline and dopamine, by catalyzing the transfer 
of a methyl group from S-adenosylmethionine. Biochemical research has established 
that the enzyme activities in patients with MDD differ from those of nondepressed 
subjects.2 The COMT gene is located at 22q 11.21. In a multicenter European study, 
an association was found between the COMT gene Val158Met (G324A) functional 
polymorphism and MDD.3 The Val allele has been reported to result in three- to fourfold 
higher activity than the Met allele.4 One report suggests that there is an association 
between higher activity of the COMT gene Val158Val-type and a poor  antidepressant Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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treatment response.5 The Met-variants of COMT gene Val-
158Met were shown to be risk variants for depressed mood 
and low motivation in depressive Swedish men.6
Brain-derived neurotrophic factor (BDNF) is a molecu-
lar substrate of stress; data have demonstrated that BDNF 
expression is reduced by stress (an important risk factor for 
MDD and posttraumatic stress disorder)7 and correlates to   
hippocampus volume in patients.8 The levels of BDNF and 
its receptor, tropomyosin-related kinase B (TrkB) receptor, 
are decreased in regions of the hippocampus in postmortem 
tissue taken from suicide victims and patients with MDD, 
and in the serum of MDD patients.9–11 Researchers have 
investigated the BDNF gene for a single nucleotide poly-
morphism (SNP) that might be linked to MDD. The most 
common BDNF SNP in humans is at codon 66, resulting in 
the Val66Met protein variant, which prevents the activity-
dependent release of BDNF.12 Men homozygous for the 
mutation might be at greater risk for MDD.13 It has been 
hypothesized that monoamine and BDNF are associated with 
the pathogenesis of MDD.14
The white matter (WM) abnormalities constitute one 
element of the pathogenesis of MDD.15–17 Various fiber tract 
alterations have been seen in MDD patients.18–22 Magnetic 
resonance imaging (MRI) is a noninvasive method used 
to examine WM abnormalities. Diffusion tensor imaging 
(DTI) is an MRI technique that can study the orientation and 
  integrity of WM fiber tracts in vivo.23 DTI-based   quantitative 
measures, such as fractional anisotropy (FA), represents intact 
myelin and axons, and has been shown to be a useful marker 
of the  microstructural changes in WM.
Although several studies using a voxel-based DTI analy-
sis demonstrated lower FA values in the frontal, temporal, 
and parietal lobes and the cerebellum of MDD patients,24–28 
such an analysis is not a mainstream of statistical parametric 
mapping and is not officially supported. Therefore, there has 
not been a consensus about the optimal method to spatially 
normalize FA images and the size of the smoothing   kernel. 
A voxel-wise approach of tract-based spatial statistics (TBSS) 
has been introduced. The TBSS method projects all subjects’ 
FA data onto an average FA tract skeleton before applying 
voxel-wise cross-subject statistics, and it minimizes the 
misalignment effects and is more robust and sensitive than 
voxel-based DTI analyses.18
The findings from individual reports of WM abnormalities 
in MDD patients indicate a widespread pattern of alterations, 
and the extent of WM abnormalities might be associated with 
clinical features. Indeed, the severity of illness and poorer 
treatment outcomes have been associated with increased 
WM pathology, indicating that patients with a greater illness 
burden are more likely to have microstructural damages.29 The 
most pronounced WM FA reductions have been observed in 
the main body and genu of the corpus callosum, consistent 
with some, but not all, DTI reports in MDD. FA values of the 
WM in the right frontal lobe, right fusiform gyrus, left frontal 
lobe, and right occipital lobe were also demonstrated to be 
reduced. Fiber tracking has shown that the main fascicles 
involved were the right inferior longitudinal fasciculus, right 
inferior fronto-occipital fasciculus, right posterior thalamic 
radiation, and interhemispheric fibers running through the 
genu and body of the corpus callosum.30
Carballedo et al31 recently reported that they observed a 
significant interaction, in the uncinated fasciculus, between 
a BDNF allele and diagnosis: patients carrying the BDNF 
Met allele had lower FA values in the uncinated fasciculus 
compared with healthy subjects carrying the Met allele. 
Kim et al32 reported an association between altered WM 
connectivity and COMT gene Val158Met polymorphism in 
panic disorder patients. We hypothesize that the COMT gene 
and the BDNF gene are associated with WM connectivity in 
MDD patients.
In the present study, therefore, we compared the status of 
polymorphism of the COMT gene or BDNF gene and DTI 
findings between drug-naïve MDD patients and age- and 
sex-matched healthy controls.
Subjects and methods
Subjects
Thirty first-episode, right-handed, treatment-naïve outpa-
tients were recruited. Major depressive episodes were diag-
nosed using the Structured Clinical Interview for Diagnostic 
and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV) according to the DSM-IV, text revision (TR) 
criteria. The severity of depression was evaluated using the 
17-item Hamilton Rating Scale for Depression (HAMD17). 
Only those patients with a HAMD17 score $14 were eligible 
for the study. Exclusion criteria were: any history of neuro-
logical disease or other physical disease, and comorbidity 
with other mental disorders (no evidence of schizoaffective 
disorder, bipolar disorder, Axis II personality disorders, or 
mental retardation). In all, 17 subjects were male, and 13 were 
female. The age range was from 20 to 67 years, with a mean ± 
standard deviation (SD) age of 44±12 years. Similarly, 30 
right-handed healthy subjects, 17 male and 13 female, with 
mean age 44±13 years were recruited from the community.
The DTI scans for all 60 subjects were performed on the 
day when each subject was enrolled. The 30 control subjects Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1185
COMT gene and white matter abnormalities in depression
were interviewed by the same psychiatrists that interviewed 
the MDD patients, using the Structured Clinical Interview 
for DSM-IV , nonpatient edition. None of the control subjects 
had a history of serious medical or neuropsychiatric illness 
or a family history of major psychiatric or neurological ill-
ness in their first-degree relatives, and all were well matched 
with the patients in terms of age, sex, and years of education. 
All subjects were given complete information about the 
procedures. Written informed consent was obtained from all 
subjects via forms approved by the local Ethics Committee 
of the University of Occupational and Environmental Health, 
Kitakyushu, Japan.
Methods
Diffusion tensor images: MRI scanning protocol
All MRI examinations were performed using a 3T MRI 
  system (Signa® EXCITE™ 3T; GE Healthcare, Little Chal-
font, UK) with an eight-channel brain phased-array coil. DTIs 
were acquired by a single-shot, spin-echo planar sequence, 
with the following parameters: TR/TE =12,000/83.3 msec; 
4 mm slice thickness; no gap; field of view =26 cm; number 
of   excitations =1, spatial resolution =1.02×1.02×4 mm. 
  Diffusion gradients (b-value of 1,000 sec/mm2) were always 
applied on two axes simultaneously around the 180-degree 
pulse. The diffusion properties were measured along 25 
noncollinear directions. The spatial distortion of diffusion-
weighted MRIs was corrected based on each T2-weighted 
echo-echo planar image (b=0 sec/mm2)33 using registration 
functional MRI of the brain (FMRIB) tools.
Image processing
Maps of FA were computed for all subjects from the DTIs, 
after eddy current correction and automatic brain   extraction 
using the FMRIB Diffusion Toolbox, which is part of the 
FMRIB Software Library (The Oxford Centre for   Functional 
MRI of the Brain, Oxford, UK).34 We performed a voxel-
wise statistical analysis of the DTI data using TBSS35 
(implemented in the FMRIB Software Library 4.1.6). The 
FA, radial diffusivity (RD), and axial diffusivity (AD) were 
created by fitting a tensor model to the raw diffusion data. 
Brain extraction was then performed using the Brain Extrac-
tion Tool 2.1.36
The FA data of all subjects were aligned into a common 
space by means of nonlinear registration.37 Next, a mean FA 
image was created and thinned to create a mean FA skeleton 
representing the centers of all tracts common to the group. 
This skeleton was thresholded at FA .0.2. Each subject’s 
aligned FA data were then projected onto this skeleton, and 
the resulting data were fed into a voxel-wise cross-subject 
statistical analysis. Subsequently, other relevant DTI output 
images (AD and RD) were projected onto the mean FA 
skeleton so that other diffusivity values could be compared 
between groups in the same spatial location.
We compared the DTI metrics between the MDD and 
control groups using a TBSS analysis.
Genotyping and serum catecholamine  
metabolites assay
Genomic DNA was extracted from peripheral leukocytes 
using a QIAamp® DNA Blood Kit (Qiagen, Venlo, the 
Netherlands) and was stored at −20°C until used for analysis. 
Genotyping for the presence of the BDNF Val66Met and 
COMT Val158Met polymorphisms was performed using 
direct sequencing in the region.
We analyzed the subjects’ plasma concentrations of homo-
vanillic acid (HVA) and 3-methoxy-4-  hydroxyphenylglycol 
(MHPG) by high-performance liquid chromatography with 
electrochemical detection (HPLC-ECD). The plasma HVA 
levels were analyzed by HPLC-ECD according to the method 
of Yeung et al,38 with slight modification. In brief, each cyano-
bonded solid-phase extraction cartridge was preconditioned 
with methanol, followed by glass-distilled water. To each 
cartridge we added 0.3 mL of plasma sample or standard, 
and 0.1 mL of working internal standard solution (5 ng of 
5-hydroxyindolecarboxylic acid in 0.01 M KH2PO4, pH 7.2). 
The samples were deproteinized with 1 mL of acetonitrile. 
After mixing by vortex and centrifugation (1,760× g, 4°C for 
10 minutes), an aliquot (5 µL) of supernatant was allowed 
to pass through the cartridge slowly, under a mild vacuum 
(15 mmHg). The cartridge was washed with 0.2 mL of dis-
tilled water and extracted containing 1 mL of ethylacetate, 
and then an aliquot was evaporated to dryness under nitrogen 
gas. After dissolution in mobile phase (200 µL), a 10 µL por-
tion of this solution was injected into the HPLC system. The 
detection limit was 0.5 ng/mL, and the calibration curve was 
linear up to 40 ng/mL. The intra- and interassay coefficients 
of variation were 6% and 8%, respectively. The recovery rate 
was more than 80%.
The subjects’ plasma MHPG levels were also analyzed 
by HPLC-ECD, according to the method of Minegishi and 
Ishizaki.39 In brief, the plasma was separated by centrifugation 
at 600× g at 4°C. Extraction was performed under a vacuum 
using Bond-Elut columns (Varian Medical Systems, Inc., Palo 
Alto, CA, USA) prepacked with 100 mg of C18-bonded silica 
(40 µm) in a 1 mL capacity disposable syringe. The columns, 
which were inserted into a vacuum chamber connected to an Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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aspirator, were prepared by washing with 1 mL methanol 
followed by 1 mL of water. After the addition of 50 µL of a 
solution of vanillyl alcohol (internal standard equivalent to 
5 ng/mL) to 1 mL of plasma, the samples were passed through 
the columns, followed by 0.75 mL of water to rinse off both 
residual samples and easily eluted hydrophilic compounds.
The adsorbed materials were eluted with 200 µL of metha-
nol to a 0.1 M phosphate buffer (pH 4.8) mixture (40:60, 
v/v [volume/volume]). A 20 µL portion of this solution was 
injected into the HPLC system. The detection limit was 0.5 
ng/mL, and the calibration curve was linear up to 40 ng/mL. 
The intra- and interassay coefficients of variation were 6% and 
8%, respectively. The recovery rate was more than 80%.
Statistical analyses
The significance threshold for between-group differences was 
set at family-wise error (FWE)-corrected P,0.05; this was 
corrected for multiple comparisons across voxels by using the 
threshold-free cluster-enhancement option. The number of 
permutations was set to 20,000 in all voxel-wise analyses. The 
chi-square test was used to compare the number of patients 
with the COMT or BDNF genotype Val/Val, and the number 
of Met-carriers in both the MDD patient and the control 
groups. The unpaired t-test was used to compare the items of 
the HAMD17 scores, and the plasma levels of MHPG and 
HVA between the Val/Val group and Met-carriers in the MDD 
patient group. The unpaired t-test was also used to compare 
serum BDNF levels between the MDD patients and the healthy 
controls. A significance level of P,0.05 was used. Statistical 
procedures were performed using the Japanese version of 
SPSS, version 15 (SPSS Inc., Chicago, IL, USA).
Results 
The genotype distributions of the COMT Val158Met poly-
morphism were determined in both the MDD patients and 
the control subjects, as shown in Table 1. The table provides 
the allele and genotype distributions as well as the chi-square 
and P-values of Hardy–Weinberg equilibria. As can be seen 
in Table 2, there were no significant differences among 
the MDD patients in each item of the HAMD17, with the 
exception that the responses to item 16 (weight loss) dif-
fered significantly between the COMT Val/Val group and 
the COMT Met-carriers.
The analysis of the plasma levels of catecholamine 
metabolites (MHPG and HVA) revealed no significant 
differences between the MDD patients and the controls 
(MHPG was 5.3±1.0 ng/mL for MDD and was 5.4±1.2 ng/mL 
for controls [P=0.23]; HVA was 5.5±1.4 ng/mL for MDD 
and was 5.1±0.8 ng/mL for the controls [P=0.13]). In addi-
tion, no significant differences between the Val/Val group 
and the Met-carriers were found in plasma MHPG, a major 
metabolite of norepinephrine (5.0±1.4 ng/mL [Val/Val 
group]; 4.9±1.5 [Met-carriers] [P=0.85]) or in plasma 
HVA, a major metabolite of dopamine (8.5±2.7 ng/mL 
[Val/Val group]; 8.7±2.7 ng/mL [Met-carriers] [P=0.81]). 
The serum BDNF levels were significantly lower in the 
MDD patients (4.8±0.4 ng/mL) compared with the controls 
(5.6±0.5 ng/mL) (P=0.044).
Table 2 Between-group comparisons of scores on each item of the 
HAMD17, in MDD patients with the BDNF gene polymorphism
HAMD 17-item Val/Val Met-carrier P-value
1 2.53±0.96 2.60±0.88 0.84
2 0.8±0.75 0.87±0.72 0.81
3 1.40±0.80 1.93±1.18 0.17
4 1.33±0.60 1.07±0.57 0.23
5 1.07±0.25 0.93±0.44 0.33
6 1.13±0.60 1.20±0.65 0.76
7 2.80±0.91 2.93±0.93 0.7
8 0.87±0.65 1.00±0.73 0.6
9 0.80±0.65 0.67±0.70 0.6
10 1.67±1.14 1.67±1.01 1
11 1.53±0.81 1.40±0.80 0.66
12 1.07±0.68 1.07±0.25 1
13 0.8±0.54 1.00±0.52 0.32
14 1.07±0.57 1.47±0.62 0.08
15 0.73±0.77 0.60±0.80 0.65
16 0.53±0.72 0.80±0.91 0.039
17 0.20±0.40 0.47±0.72 0.23
Total 19.50±6.35 21.70±4.91 0.31
Notes: 1, Depressed mood; 2, Feeling of guilt; 3, Suicide; 4, Insomnia early; 5, Insomnia 
middle; 6, Insomnia late; 7, Work and activity; 8, Retardation; 9, Agitation; 10, Anxiety 
(psychological); 1 1,  Anxiety  (somatic); 1 2,  Somatic  symptoms  (gastrointestinal); 
13, Somatic symptoms (general); 14, Genital symptoms; 15, Hypochondriasis; 16, 
Loss of weight; 17, Insight.
Abbreviations: BDNF, brain-derived neurotrophic factor; HAMD17, 17-item Hamilton 
Rating Scale for Depression; MDD, major depressive disorder.
Table 1 Gene distribution of COMT and BDNF in patients with 
MDD and healthy controls
Control χ2 P-value Number 
of  
patients
χ2 P-value
COMT Val158Met
GG 10 9
GA 18 2.566 0.1099 16 0.222 0.5377
AA 2 5
BDNF Val66Met
GG 18 15
GA 10 0.14 0.7082 8 1.12 0.2900
AA 2 7
Abbreviations:  BDNF,  brain-derived  neurotrophic  factor;  COMT,  catechol-O-
methyltransferase.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Regarding BDNF Val66Met, no significant   differences 
between the Val/Val group and the Met-carriers were observed 
in plasma MHPG (5.0±1.4 ng/mL [Val/Val group]; 4.9±1.5 
[Met-carriers] [P=0.85]), plasma HVA (5.3±1.1 ng/mL 
[Val/Val group]; 5.0±1.3 [Met-carriers] [P=0.54]), or serum 
BDNF (5.4±1.2 ng/mL [Val/Val group]; 4.8±1.6 [Met-
carriers] [P=0.39]). No differences were observed in any 
items of the HAMD17 between the Val/Val genotype and 
the Met-carriers (Table 3).
In the voxel-wise-based group comparison, no significant 
differences were observed regarding FA, AD, or RD, in all 
patients compared with the controls. We found a significant 
FA decrease (P,0.05) within the temporal lobe WM in 
the Met-carriers among the MDD patients compared with 
those of the healthy controls (Figure 1A–C), on the basis 
of the Johns Hopkins University (JHU) white-matter trac-
tography atlas and the International Consortium for Brain 
Mapping DTI-81 WM labels (part of the FMRIB Software 
Library package). In the voxel-wise-based group comparison, 
there was no significant difference in FA, AD, or RD, between 
the MDD patients and the healthy controls.
After dividing the MDD patients into genotype subgroups, 
we found a significant FA decrease (P,0.05) in the tempo-
ral lobe among the MDD patients who were Met-carriers  compared with the corresponding values among the healthy 
controls (Figure 1A–C). Significantly decreased AD in the tem-
poral lobe (P,0.05) was also found in the Met-carrier MDD 
patients compared with the healthy controls (Figure 1D–F). 
Significantly decreased AD in the temporal lobe (P,0.05) was 
also found in the MDD patients compared with the controls 
(Figure 1D–F). Moreover, the genotype–  diagnostic interac-
tion effect on FA was seen in the same   position (uncorrected 
P,0.05), although no voxels could survive after the correction 
for multiple comparisons (FWE ,0.05). The results of the 
image analyses are shown in Table 4.
No significant differences were observed in FA or AD, at 
any brain regions, between the MDD patients with the COMT 
Table 3 Between-group comparisons of scores on each item of 
the HAMD17 for the two groups of patients with MDD
HAMD 17-item Val/Val Met-carrier P-value
1 2.11±0.34 2.32±0.64 0.71
2 0.73±0.75 0.80±0.69 0.65
3 1.67±0.59 1.81±1.03 0.19
4 1.48±0.76 1.29±0.49 0.18
5 1.02±0.29 1.09±0.38 0.30
6 1.13±0.60 1.20±0.65 0.76
7 2.49±0.67 2.99±1.08 0.52
8 0.91±0.72 1.14±0.81 0.53
9 0.92±0.54 0.71±0.52 0.49
10 1.82±1.02 1.52±0.94 0.78
11 1.23±0.74 1.57±0.79 0.72
12 0.98±0.68 1.12±0.43 0.92
13 0.87±0.63 1.14±0.61 0.43
14 1.21±0.62 1.44±0.78 0.11
15 0.65±0.52 0.63±0.79 0.59
16 0.53±0.69 0.78±0.88 0.13
17 0.37±0.41 0.52±0.51 0.49
Total 20.33±7.29 20.97±5.84 0.51
Notes: 1 ,  Depressed  mood; 2 ,  Feeling  of  guilt; 3 ,  Suicide; 4 ,  Insomnia  early; 
5,  Insomnia  middle; 6 ,  Insomnia  late; 7 ,  Work  and  activity; 8 ,  Retardation; 
9,  Agitation; 1 0,  Anxiety  (psychological); 1 1,  Anxiety  (somatic); 1 2,  Somatic 
symptoms (gastrointestinal); 13, Somatic symptoms (general); 14, Genital symptoms; 
15, Hypochondriasis; 16, Loss of weight; 17, Insight.
Abbreviations:  HAMD17, 1 7-item  Hamilton  Rating  Scale  for  Depression;   
MDD, major depressive disorder.
Figure 1 Corrected P-maps for the COMT gene polymorphism. 
Notes: These maps show the regions where FA is reduced in the red voxels 
(A–C), where AD is reduced in the red voxels (D–F), and where RD shows no 
change (G–I). The FA, AD, and RD skeletons are projected in green on the MNI 
152 template (Montreal Neurological Institute, Montreal, QC, Canada) average 
brain section. 
Abbreviations: AD, axial diffusivity; COMT, catechol-O-methyltransferase; FA, fractional 
anisotropy; RD, radial diffusivity.
Table 4 The results of image analyses
Anatomical  
regions
Cluster  
size
P-value  
(FWE-corrected)
MNI coordinate
x y z
FA analysis (HS . MDD in Met carriers)
Right temporal  
lobe
81 0.046 54 87 84
10 0.049 53 91 80
AD analysis (HS . MDD in Met carriers)
Right temporal  
lobe
151 0.046 58 90 87
9 0.049 51 81 71
Abbreviations: AD, axial diffusivity; FA, fractional anisotropy; FWE, family-wise 
error; HS, healthy subjects; MD, mean diffusivity; MDD, major depressive disorder; 
MNI, Montreal Neurological Institute.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Val/Val genotype and the healthy controls with the COMT 
Val/Val genotype. No significant difference was observed 
in RD between the MDD patients and the healthy controls, 
both among the COMT Val/Val group and the COMT Met-
carriers (Figure 1G–I). In addition, there were no significant 
differences regarding FA, AD, or RD between the Val/Val 
group and the Met-carriers among the MDD patients, and no 
correlations in FA, AD, or RD were observed, at any regions 
of the brain, between the MDD patients and the healthy 
controls, both those with the BDNF Val/Val genotype and 
the BDNF Met-carriers (Table 4).
Discussion
In the genotype comparison (significant genotype–diagnosis 
interactions), we found that the reduction of the FA values 
in the temporal lobe was significantly larger in the MDD 
patients compared with the healthy subjects. FA has been 
shown to have an increased sensitivity to WM damage, as 
its decrease has been reported in the normal-appearing WM 
of patients with MDD.24 The use of other DTI parameters, 
such as AD, which is related to axonal loss, and RD, which is 
associated with demyelination,37,40 may increase the specific-
ity of DTI to particular microstructural abnormalities. The 
most noteworthy finding in the present study was that the 
FA and AD, but not the RD, in the temporal lobe in the Met-
carriers with MDD were significantly decreased compared 
with those in the healthy controls. These results may indicate 
that neuronal degeneration (axonal loss) can occur in the 
temporal lobe of Met-carriers with MDD.
In contrast, Seok et al41 recently reported that FA reduction 
in the temporal lobe was significant only in the MDD patients 
with the Val/Val group of COMT Val158Met polymorphism. 
This finding indicates that MDD patients with a homozygote 
Val gene might have further abnormalities and brain patho-
logical changes. Taken together, the above-described findings 
show that it is controversial whether the COMT Val158Met 
polymorphism is associated with structural changes of WM 
in the temporal lobe.
However, no significant differences were found in the 
plasma levels of MHPG and HVA between the present MDD 
patients and the control subjects. Depression is a heteroge-
neous condition characterized by multiple symptoms and 
subtypes. The different symptoms and subtypes are likely 
mediated by different neurocircuitry, and neurotransmitters 
such as noradrenaline, dopamine, and serotonin, and they 
might or might not be present in any particular individual 
with MDD. MDD might be characterized by an increase or 
a decrease in certain symptoms.
We reported that MDD patients with high plasma MHPG 
demonstrated severe anxiety and agitation, whereas those with 
low MHPG and/or HVA demonstrated severe psychomotor 
retardation.42,43 We suspect that this is one of the reasons that 
no significant between-group differences were found in the 
catecholamine metabolites, in the present study.
In addition, each component of depressive symptoms 
might be related to the some brain regions and neurocircuits. 
  Anhedonia, for example, has been found to be positively cor-
related with the ventromedial prefrontal cortex activity and 
negatively correlated with amygdala/ventral striatal activity in 
response to “happy” stimuli, using functional MRI (fMRI).44 
Psychomotor symptoms have been associated with frontal 
and caudate abnormalities in depression.45 A recent fMRI 
study has shown that vulnerability to MDD is associated 
with temporofrontolimbic decoupling that is selective for 
self-blaming feelings.46
According to the meta-analysis of Liao et al30 using 
DTI, there are four consistent locations of decreased FA in 
patients with MDD: WM in the right frontal lobe, the right 
fusiform gyrus, the left frontal lobe, and the occipital lobe. 
Fiber tracking showed that the main fascicles involved were 
the right inferior fronto-occipital fasciculus, the right poste-
rior thalamic radiation, and interhemispheric fibers running 
through the genu and the body of the corpus callosum.
Taken together, these results indicate that COMT gene 
Val158Met polymorphism did not reflect the plasma and cere-
brospinal fluid levels of catecholamine metabolites. The weight 
loss item scores of the HAMD17 were significantly lower in the 
present COMT Val/Val group than in the Met-carriers. It might be 
possible that the higher activity of COMT leads to reduced physi-
cal activity by influencing the catecholaminergic pathways.
The specificity of WM hyperintensities to age-associated 
vascular depression47 reinforces the notion that MDD is 
a heterogeneous disorder. Although the data suggest that 
T2-weighted WM is related to late-onset MDD, findings 
suggestive of microstructural WM changes, as evinced by 
DTI, in young adults with MDD were reported by Li et al.48 
The age-associated relationship between WM and MDD may 
preclude the use of this trait to identify young individuals 
at risk of developing MDD. Nevertheless, an understanding 
of the mechanisms by which microvascular lesions lead to 
depression may help elucidate important pathophysiological 
pathways and facilitate the development of new treatments. In 
the present study, however, no correlations were found with 
the BDNF Val/Met polymorphism in patients with MDD.
On the other hand, Carballedo et al31 reported that 
they observed a significant interaction between BDNF Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1189
COMT gene and white matter abnormalities in depression
alleles in the uncinate fasciculus and diagnosis. In short, 
their patients with the BDNF Met allele had smaller FA in 
the uncinate fasciculus compared with the patients in the 
Val/Val group and compared with healthy controls with 
Met allele. In the present study, we did not examine the 
regions of the temporal lobe in detail. One of the reasons 
for the discrepancy between the results of Carballedo 
et al31 and those of the present study was that our MDD 
patients were at the early stage of depressive state and 
were drug-naïve.
Our finding that the serum BDNF levels in the MDD 
patients were lower than those in the healthy controls is in 
agreement with previous reports.11,49–51 We also found that 
the BDNF gene Val66Met polymorphism was not associated 
with serum BDNF levels in patients with MDD and that the 
BDNF Val66Met polymorphism is independent of the WM 
disturbance in MDD. Taken together, these results indicate 
that the BDNF gene Val66Met polymorphism is not critical 
for WM disturbances in patients with MDD.
The present study has several limitations. The sample 
size was too small to allow a second statistical analysis. The 
sample was heterogeneous, and the severity of illness was 
relatively moderate. A replication study that accounts for 
these limitations should be performed to confirm our pre-
liminary results. Since the COMT gene Met-carriers showed 
more decreased body weight (Table 2), the possibility that the 
finding reflected the changed distribution in the brain could 
not be completely ruled out.
In conclusion, we observed an association between the 
COMT gene Val158Met polymorphism and the reduction 
of FA and AD, but not RD, in the temporal lobe of patients 
with MDD.
Acknowledgment
Professor Jun Nakamura was supported by a grant from the 
Ministry of Education, Culture, Sports, Science and Techn-
ology of Japan (grant number 21591494).
Disclosure
Professor Jun Nakamura has received grant support from 
Astellas Pharma, Tanabe-Mitsubishi Pharmaceutical Co 
Ltd, Otsuka Pharmaceutical Co Ltd, Eli Lilly and Company, 
Pfizer, Inc., and GlaxoSmithKline plc. The authors report no 
other conflicts of interest in this work.
References
1.  Yoshimura R, Nakamura J, Shinkai K, Ueda N. Clinical response to 
antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: 
mini review. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4): 
611–616.
  2.  Karege F, Bovier P, Gaillard JM, Tissot R. The decrease of   erythrocyte 
catechol-O-methyltransferase activity in depressed patients and 
its diagnostic significance. Acta Psychiatr Scand. 1987;76(3): 
303–308.
  3.  Massat I, Souery D, Del-Favero J, et al. Association between COMT 
(Val158Met) functional polymorphism and early onset in patients with 
major depressive disorder in a European multicenter genetic association 
study. Mol Psychiatry. 2005;10(6):598–605.
  4.  Lachman HM, Morrow B, Shprintzen R, et al. Association of codon 
108/158 catechol-O-methyltransferase gene polymorphism with the 
psychiatric manifestations of velo-cardio-facial syndrome. Am J Med 
Genet. 1996;67(5):468–472.
  5.  Baune BT, Hohoff C, Berger K, et al. Association of the COMT 
  val158met variant with antidepressant treatment response in major 
depression. Neuropsychopharmacology. 2008;33(4):924–932.
  6.  Åberg E, Fandiño-Losada A, Sjöholm LK, Forsell Y, Lavebratt C.   
The functional Val158Met polymorphism in catechol-O-
  methyltransferase (COMT) is associated with depression and   motivation 
in men from a Swedish population-based study. J Affect Disord. 
2011;129(1–3):158–166.
  7.  Martinowich K, Manji H, Lu B. New insights into BDNF function in 
depression and anxiety. Nat Neurosci. 2007;10(9):1089–1093.
  8.  Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, 
  Charney DS. Hippocampal volume reduction in major depression. 
Am J   Psychiatry. 2000;157(1):115–118.
  9.  Castrén E, Rantamäki T. The role of BDNF and its receptors 
in   depression and antidepressant drug action: Reactivation of 
  developmental   plasticity. Dev Neurobiol. 2010;70(5):289–297.
  10.  Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased 
BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus 
of individuals with schizophrenia and mood disorders. J Psychiatry 
Neurosci. 2011;36(3):195–203.
  11.  Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, 
Elzinga BM. Serum BDNF concentrations as peripheral manifestations 
of depression: evidence from a systematic review and meta-analyses on 
179 associations (N=9484). Mol Psychiatry. Epub August 20, 2013.
  12.  Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met 
  polymorphism affects activity-dependent secretion of BDNF and human 
memory and hippocampal function. Cell. 2003;112(2):257–269.
  13.  Frielingsdorf H, Bath KG, Soliman F, Difede J, Casey BJ, Lee FS. 
Variant brain-derived neurotrophic factor Val66Met endophenotypes: 
implications for posttraumatic stress disorder. Ann N Y Acad Sci. 
2010;1208:150–157.
  14.  aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms 
in major depressive disorder. CMAJ. 2009;180(3):305–313.
  15.  Fields RD. White matter in learning, cognition and psychiatric disorders. 
Trends Neurosci. 2008;31(7):361–370.
  16.  Herrmann  LL,  Le  Masurier  M,  Ebmeier  KP. White  matter 
  hyperintensities in late life depression: a systematic review. J Neurol 
Neurosurg Psychiatry. 2008;79(6):619–624.
  17.  Kumar A, Cook IA. White matter injury, neural connectivity and the 
pathophysiology of psychiatric disorders. Dev Neurosci. 2002;24(4): 
255–261.
  18.  Kieseppä T, Eerola M, Mäntylä R, et al. Major depressive disorder 
and white matter abnormalities: a diffusion tensor imaging study with 
tract-based spatial statistics. J Affect Disord. 2010;120(1–3):240–244.
  19.  Korgaonkar MS, Grieve SM, Koslow SH, Gabrieli JD, Gordon E, 
  Williams LM. Loss of white matter integrity in major depressive 
  disorder: evidence using tract-based spatial statistical analysis of 
  diffusion tensor imaging. Hum Brain Mapp. 2011;32(12):2161–2171.
  20.  Zhu X, Wang X, Xiao J, Zhong M, Liao J, Yao S. Altered white   matter 
integrity in first-episode, treatment-naive young adults with major 
depressive disorder: a tract-based spatial statistics study. Brain Res. 
2011;1369:223–229.
  21.  Cullen KR, Klimes-Dougan B, Mueller BA, et al. Altered white matter 
microstructure in adolescents with major depression: A preliminary 
study. J Am Acad Child Adolesc Psychiatry. 2010;49(2):173–183.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1190
Hayashi et al
  22.  Zuo N, Fang J, Lv X, et al. White matter abnormalities in major 
depression: a tract-based spatial statistics and rumination study. PLoS 
One. 2012;7(5):e37561.
  23.  Sexton CE, Mackay CE, Ebmeier KP. A systematic review of 
diffusion tensor imaging studies in affective disorders. Biol Psychiatry. 
2009;66(9):814–823.
  24.  Henderson CE, Higginson JS, Barrance PJ. Comparison of MRI-based 
estimates of articular cartilage contact area in the tibiofemoral joint. J 
Biomech Eng. 2011;133(1)014502.
  25.  Ma N, Li L, Shu N, et al. White matter abnormalities in first-episode, 
treatment-naive young adults with major depressive disorder. Am J 
Psychiatry. 2007;164(5):823–826.
  26.  Wu F, Tang Y, Xu K, et al. Whiter matter abnormalities in medication-
naive subjects with a single short-duration episode of major depressive 
disorder. Psychiatry Res. 2011;191(1):80–83.
  27.  Ouyang X, Tao HJ, Liu HH, et al. White matter integrity deficit in 
treatment-naïve adult patients with major depressive disorder. East 
Asian Arch Psychiatry. 2011;21(1):5–9.
  28.  Jia Z, Huang X, Wu Q, et al. High-field magnetic resonance imaging of 
suicidality in patients with major depressive disorder. Am J Psychiatry. 
2010;167(11):1381–1390.
  29.  de Diego-Adeliño J, Pires P, Gómez-Ansón B, et al. Microstructural 
white-matter abnormalities associated with treatment resistance, 
  severity and duration of illness in major depression. Psychol Med. Epub 
August 21, 2013.
  30.  Liao Y, Huang X, Wu Q, et al. Is depression a disconnection syndrome? 
Meta-analysis of diffusion tensor imaging studies in patients with MDD. 
J Psychiatry Neurosci. 2012;38(1):49–56.
  31.  Carballedo A, Amico F, Ugwu I, et al. Reduced fractional anisotropy in 
the uncinate fasciculus in patients with major depression carrying the 
met-allele of the Val66Met brain-derived neurotrophic factor genotype. 
Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):537–548.
  32. Kim B, Yoo E, Lee JY, et al. The effects of the catechol-O-
  methyltransferase val158met polymorphism on white matter connectivity 
in patients with panic disorder. J Affect Disord. 2013;147(1–3):64–71.
  33.  Haselgrove JC, Moore JR. Correction for distortion of echo-planar 
images used to calculate the apparent diffusion coefficient. Magn Reson 
Med. 1996;36(6):960–964.
  34.  Smith SM, Jenkinson M, Woolrich MW, et al. Advances in   functional 
and structural MR image analysis and implementation as FSL. 
  Neuroimage. 2004;23 Suppl 1:S208–S219.
  35.  Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based 
  spatial   statistics: voxelwise analysis of multi-subject diffusion data. 
  Neuroimage. 2006;31(4):1487–1505.
  36.  Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 
2002;17(3):143–155.
  37.  Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. 
Nonrigid registration using free-form deformations: application to breast 
MR images. IEEE Trans Med Imaging. 1999;18(8):712–721.
  38.  Yeung PK, Buckley SJ, Pedder SC, Dingemanse J. Determination of 3,4-
dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human 
plasma by a simple and rapid high-performance liquid chromatography 
assay. J Pharm Sci. 1996;85(4):451–453.
  39.  Minegishi A, Ishizaki T. Determination of free 3-methoxy-4-
  hydroxyphenylglycol with several other monoamine metabolites in 
plasma by high-performance liquid chromatography with amperometric 
detection. J Chromatogr. 1984;311(1):51–57.
  40.  Brett M, Leff AP, Rorden C, Ashburner J. Spatial normalization of brain 
images with focal lesions using cost function masking. Neuroimage. 
2001;14(2):486–500.
  41.  Seok JH, Choi S, Lim HK, Lee SH, Kim I, Ham BJ. Effect of the COMT 
val158met polymorphism on white matter connectivity in patients with 
major depressive disorder. Neurosci Lett. 2013;545:35–39.
  42.  Ueda N, Yoshimura R, Shinkai K, Nakamura J. Plasma levels of 
  catecholamine metabolites predict the response to   sulpiride or 
  fluvoxamine in major depression. Pharmacopsychiatry. 2002;35(5): 
175–181.
  43.  Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J.   Associations 
between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) 
levels and clinical responses with respect to milnacipran versus 
  paroxetine treatment. J Clin Psychopharmacol. 2004;24(1):11–17.
  44.  Stuhrmann A, Dohm K, Kugel H, et al. Mood-congruent amygdala 
responses to subliminally presented facial expressions in major 
  depression: associations with anhedonia. J Psychiatry Neurosci. 
2013;38(4):249–258.
  45.  Der-Avakian A, Markou A. The neurobiology of anhedonia and other 
reward-related deficits. Trends Neurosci. 2012;35(1):68–77.
  46.  Green S, Lambon Ralph MA, Moll J, Deakin JF, Zahn R.   Guilt-selective 
functional disconnection of anterior temporal and subgenual cortices 
in major depressive disorder. Arch Gen Psychiatry. 2012;69(10): 
1014–1021.
  47.  Sneed JR, Rindskopf D, Steffens DC, Krishnan KR, Roose SP. 
The   vascular depression subtype: evidence of internal validity.   
Biol   Psychiatry. 2008;64(6):491–497.
  48.  Li L, Ma N, Li Z, et al. Prefrontal white matter abnormalities in young 
adult with major depressive disorder: a diffusion tensor imaging study. 
Brain Res. 2007;1168:124–128.
  49.  Bocchio-Chiavetto L, Bagnardi V , Zanardini R, et al. Serum and plasma 
BDNF levels in major depression: a replication study and meta-analyses. 
World J Biol Psychiatry. 2010;11(6):763–773.
  50.  Fernandes BS, Gama CS, Ceresér KM, et al. Brain-derived   neurotrophic 
factor as a state-marker of mood episodes in bipolar disorders:   
a systematic review and meta-regression analysis. J Psychiatr Res. 
2011;45(8):995–1004.
  51.  Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic 
  factor, depression, and antidepressant medications: meta-analyses and 
  implications. Biol Psychiatry. 2008;64(6):527–532.